Clinical Trials Logo
  1. Home
  2. Hepatorenal Syndrome
  3. NCT06095440

A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center

Hepatorenal Syndrome Clinical Trial

Official title:
A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center

Clinical Trial Summary

Hepatorenal syndrome (HRS) is a common cause of acute kidney injury (AKI) in patients with liver disease [1]. Increased activity and presence of vasodilators such as nitric oxide in cirrhotic patients leads to vasodilation, especially in the splanchnic circulation, resulting in hemodynamic changes that precipitate renal injury [1]. Patients may present with elevated serum creatinine (Cr), benign urine sediment, and low urine sodium [1].

Clinical Trial Description

There are two main classifications of HRS: HRS-AKI (previously known as type 1 HRS) and diuretic-resistant ascites (previously known as type 2 HRS) [1]. The ultimate treatment for patients with HRS is to improve hepatic function via treatment of underlying etiology or liver transplantation; however, this is not always immediately possible due to the high demand for liver transplantation among other factors [1]. Continuous renal replacement therapy (CRRT) can also be considered, especially in patients with severe electrolyte derangements such as hypokalemia or pulmonary edema, that are not responding to medical therapy [1]. Often, CRRT is used as a bridging therapy to stabilize patients until they are optimized for receiving a liver transplant [1, 2]. CRRT, however, comes with its own risks and disadvantages such as hypotension and increased risk of cardiac adverse events [2]. In certain cases, transjugular intrahepatic portosystemic shunts (TIPS) can benefit patients with HRS by reducing portal pressure resulting in increase in renal perfusion [1]. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06095440
Study type Observational
Source Methodist Health System
Contact Colette Ngo Ndjom, MS
Phone 214-947-1281
Email MHSIRB@mhd.com
Status Recruiting
Phase
Start date May 13, 2023
Completion date May 13, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT00370253 - Noradrenalin vs Terlipressin in Hepatorenal Syndrome Phase 3
Completed NCT00359853 - Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis Phase 4
Completed NCT01436500 - Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Phase 2
Completed NCT01143246 - A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin Phase 3
Recruiting NCT05346393 - HRS-AKI Treatment With TIPS in Patients With Cirrhosis N/A
Terminated NCT00734136 - Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome N/A
Terminated NCT00742339 - Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome Phase 2/Phase 3
Completed NCT02097784 - Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury N/A
Recruiting NCT04898010 - The Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI) and Hepatorenal Syndrome (HRS) Type I N/A
Recruiting NCT05875948 - Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome Phase 2
Completed NCT04416282 - Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure. N/A
Recruiting NCT02049125 - Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis N/A
Completed NCT00764049 - Single Pass Albumin Dialysis in Patients With Cirrhosis Phase 1/Phase 2
Completed NCT00089570 - Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1 Phase 3
Withdrawn NCT01587222 - Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure Phase 2
Recruiting NCT02489864 - The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Phase 4
Recruiting NCT02434445 - Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients N/A
Completed NCT02770716 - Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1 Phase 3
Completed NCT05387811 - International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project
Withdrawn NCT04048707 - Angiotensin 2 for Hepatorenal Syndrome Phase 2